Page 43 - SaxoCell Annual Report22/23
P. 43

Mod.         OPTIX
               ATMP







             Within  the  OPTIX  project,  an  optimized  manufacturing  process  for  antibody-modified  cell
             transplantation  (Palintra®)  will  be  developed  and  clinically  implemented.  The  aim  is  to  reduce
             graft-vs-host  disease  (GvHD)  in  the  treatment  of  hematological  neoplasms  while  preserving  the
             graft-vs-leukemia effect.


             Project lead: Tcell Tolerance GmbH, Lilly Stahl

             Partners:  Fraunhofer  IZI,  Leipzig  University  Hospital,  Dresden  University  Hospital,  Chemnitz
             Hospital, Tcell Tolerance GmbH

             Palintra®  was  developed  as  a  novel  therapeutic  strategy  for  GvHD  prevention  by  ex-vivo
             incubation of an allogeneic cell graft with the anti-CD4 antibody MAX.16H5 to an ATMP.






























                                                                                                              38
   38   39   40   41   42   43   44   45   46   47   48